© 2011, Crown Copyright.
Included under terms of UK Non-commercial Government License.
Bookshelf ID: NBK97482
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Picot J, Cooper K, Bryant J, et al. The Clinical Effectiveness and Cost-Effectiveness of Bortezomib and Thalidomide in Combination Regimens with an Alkylating Agent and a Corticosteroid for the First-Line Treatment of Multiple Myeloma: A Systematic Review and Economic Evaluation. Southampton (UK): NIHR Journals Library; 2011 Dec. (Health Technology Assessment, No. 15.41.)
The Clinical Effectiveness and Cost-Effectiveness of Bortezomib and Thalidomide in Combination Regimens with an Alkylating Agent and a Corticosteroid for the First-Line Treatment of Multiple Myeloma: A Systematic Review and Economic Evaluation.
Show detailsKarnofsky performance status
- 100% – normal, no complaints, no signs of disease
- 90% – capable of normal activity, few symptoms or signs of disease
- 80% – normal activity with some difficulty, some symptoms or signs
- 70% – caring for self, not capable of normal activity or work
- 60% – requiring some help, can take care of most personal requirements
- 50% – requires help often, requires frequent medical care
- 40% – disabled, requires special care and help
- 30% – severely disabled, hospital admission indicated but no risk of death
- 20% – very ill, urgently requiring admission, requires supportive measures or treatment
- 10% – moribund, rapidly progressive fatal disease processes
- 0% – death.
WHO performance status scores
- 0 –Asymptomatic (fully active, able to carry on all pre-disease activities without restriction).
- 1 – Symptomatic but completely ambulatory (restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; for example, light housework, office work).
- 2 – Symptomatic, < 50% in bed during the day (ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours).
- 3 – Symptomatic, > 50% in bed, but not bedbound (capable of only limited self-care, confined to bed or chair 50% or more of waking hours).
- 4 – Bedbound (completely disabled, cannot carry on any self-care, totally confined to bed or chair).
- 5 – Death.
- Karnofsky performance status and WHO performance status scores - The Clinical Ef...Karnofsky performance status and WHO performance status scores - The Clinical Effectiveness and Cost-Effectiveness of Bortezomib and Thalidomide in Combination Regimens with an Alkylating Agent and a Corticosteroid for the First-Line Treatment of Multiple Myeloma: A Systematic Review and Economic Evaluation
Your browsing activity is empty.
Activity recording is turned off.
See more...